In vitro and in vivo characterization of intrinsic sympathomimetic activity in normal and heart failure rats

Journal of Pharmacology and Experimental Therapeutics

Volumn 289, Issue 1, 1999, Pages 48-53

  Willette, Robert N ^a   Aiyar, Nambi ^a   Yue, Tian Li ^a   Mitchell, Marcus P ^a   Disa, Jyoti ^a   Storer, Barbara L ^a   Naselsky, Diane P ^a   Stadel, Jeffery M ^a   Ohlstein, Eliot H ^a   Ruffolo Jr , Robert R ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3 ISOPROPYLAMINO 1 (7 METHYL 4 INDANYLOXY) 2 BUTANOL; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR; BISOPROLOL; BUCINDOLOL; CARVEDILOL; CYCLIC AMP; PARTIAL AGONIST; PROPRANOLOL; XAMOTEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; ENZYME ACTIVITY; HEART FAILURE; HEART MUSCLE CELL; HEART RATE; INTRAVENOUS DRUG ADMINISTRATION; INTRINSIC SYMPATHOMIMETIC ACTIVITY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SPONTANEOUSLY HYPERTENSIVE RAT;

EID: 0032925114     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Bohm M, Mittmann C, Schwinger RHG and Erdmann E (1990) Effects of xamoterol on inotropic and lusitropic properties of the human myocardium and on adenylate cyclase activity. Am Heart J 120:1381-1392.
2. Bohm M, Schultz C, Schwinger RHG and Erdmann E (1992) Positive inotropic effects due to partial agonist activity of the β-adrenoceptor antagonist celiprolol following amplification of cAMP formation in failing human myocardium. J Cardiovasc Pharmacol 20:479-489.
3. 1-receptor down regulation in heart failure. Circ Res 59:297-309.
4. Bristow MR, Ginsburg R, Minobe W, Cubicciotti RS, Sageman WS, Lurie K, Billingham ME, Harrison DC and Stinson EB (1982) Decreased catecholamine sensitivity and β-adrenergic receptor density in failing human hearts. N J Med 307:205-211.
5. Bristow MR, Larrabee P, Minobe W, Roden R, Skerl L, Klein J, Handwerger D, Port JD and Muller-Beckman B (1992a) Receptor pharmacology of carvedilol in the human heart. J Cardiovasc Pharmacol. 19(Suppl 1):S68-S80.
6. Bristow MR, Larrabee P, Muller-Beckman B, Minobe W, Roden R, Skerl L, Klein J, Handwerger D and Port JD (1992) Effects of carvedilol on adrenergic receptor pharmacology in human ventricular myocardium and lymphocytes. Clin Invest 70:S105-113.
7. Deitchman D, Perhach JL and Snyder RW (1980) Beta-adrenoceptor and cardiovascular effects of MJ 13105 (bucindolol) in anesthetized dogs and rats. Eur J Pharmacol 61:263-277.
8. Dickinson KEJ and Nahorski RR (1983) Agonist binding to mammalian beta-1 and beta-2 adrenoceptors: Modulation by guanine nucleotide and magnesium. J Recept Res 3:123-135.
9. Doughty RN and Sharpe N (1997) Beat-adrenergic blocking agents in the treatment of congestive heart failure: Mechanism and clinical results. Annu Rev Med 48:103-114
10. Hash TW and Prisant LM (1997) Beat-blocker use in systolic heart failure and dilated cardiomyopathy. J Clin Pharmacol 37:7-19.
11. Hershberger RE, Wynn JR, Sundberg L and Bristow MR (1990) Mechanism of action of bucindolol in human ventricular myocardium. J Cardiovasc Pharmacol 15:959-967.
12. Hicks PE, Cavero I, Manoury P, Lefevre-Borg F and Langer SZ (1987) Comparative analysis of beta-1 adrenoceptor agonist and antagonist potency and selectivity of cicloprolol, xamoterol and pindolol. J Pharmacol Exp Ther 242:1025-1034.
13. Imai Y, Watanabe N, Hahimoto J, Nishiyama A, Sakuma H, Sekino H, Omata K and Abe K (1995) Muscle cramps and elevated creatinine phosphokinase levels induced by beta-adrenoceptor blockers. Eur J Clin Pharmacol 48:29-34.
14. Iwaki K, Sukatme VP, Shubeita HE and Chien KR (1990) Alpha-and beta-adrenergic stimulation induces distinct patterns of immediate early gene expression in neonatal rat myocardial cells. J Biol Chem 265:13809-13817.
15. Louis WJ, Drummer OH and Tung L-H (1990) Pharmacology of celiprolol. Cardiovasc Drugs Ther 4:1281-1286.
16. Nichols AJ, Sulpizio AC, Ashton DJ, Hieble JP and Ruffolo RR (1989) In vitro pharmacologic profile of the novel beta-adrenoceptor antagonist and vasodilator, carvedilol. Pharmacology 39:327-336.
17. Northcote R (1987) The clinical significance of intrinsic sympathomimetic activity. Int J Cardiol 15:133-150.
18. Packer M (1988) Modulation of functional capacity and survival in congestive heart failure. Postgrad Med. 83(Suppl):96-103.
19. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM and Shusterman NH (1996) The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 334:1349-1397.
20. Panfilov V, Wahlquist I and Olsson G (1995) Use of beta-adrenoceptor blockers in patients with congestive heart failure. Cardiovasc Drugs Ther 9:273-287.
21. Persson H, Rythe'n-Alder E, Melcher A and Erhardt L (1995) Effects of beta receptor antagonists in patients with clinical evidence of heart failure after myocardial infarction: Double blind comparison of metoprolol and xamoterol. Br Heart J 74:140-148.
22. Soriano JB, Hoes AW, Meems L and Grobbee DE (1997) Increased survival with beta-blockers: Importance of ancillary properties. Prog Cardiovasc Dis 39:445-456.
23. Strein K, Spooner G, Muller-Beckmann B and Barlsch W (1987) Pharmacological profile of carvedilol, a compound with beta-blocking and vasodilating properties. J Cardiovasc Pharmacol. 10(Suppl 11):S33-S41.
24. The BEST Steering Committee (1995) Design of the Beta-Blocker Evaluation Survival Trial (BEST). Am J Cardiol 75:1220-1223.
25. The CIBIS II Scientific Committee (1997) Design of the Cardiac Insufficiency Bisoprolol Study II. Fundam Clin Pharm 11:138-142.
26. The Xamoterol in Severe Heart Failure Study Group (1990) Xamoterol in severe heart failure. Lancet 336:1-6.
27. Willette RN, Sauermelch CF and Hieble JP (1990) Role of alpha-1 and alpha-2 adrenoceptors in the sympathetic control of the proximal urethra. J Pharmacol Exp Ther 252:706-710.